203 related articles for article (PubMed ID: 36862804)
1. Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer.
Pradat Y; Viot J; Yurchenko AA; Gunbin K; Cerbone L; Deloger M; Grisay G; Verlingue L; Scott V; Padioleau I; Panunzi L; Michiels S; Hollebecque A; Jules-Clément G; Mezquita L; Lainé A; Loriot Y; Besse B; Friboulet L; André F; Cournède PH; Gautheret D; Nikolaev SI
Cancer Discov; 2023 May; 13(5):1116-1143. PubMed ID: 36862804
[TBL] [Abstract][Full Text] [Related]
2. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Application of a Neural Network Whole Transcriptome-Based Pan-Cancer Method for Diagnosis of Primary and Metastatic Cancers.
Grewal JK; Tessier-Cloutier B; Jones M; Gakkhar S; Ma Y; Moore R; Mungall AJ; Zhao Y; Taylor MD; Gelmon K; Lim H; Renouf D; Laskin J; Marra M; Yip S; Jones SJM
JAMA Netw Open; 2019 Apr; 2(4):e192597. PubMed ID: 31026023
[TBL] [Abstract][Full Text] [Related]
5. Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities.
Craig DW; O'Shaughnessy JA; Kiefer JA; Aldrich J; Sinari S; Moses TM; Wong S; Dinh J; Christoforides A; Blum JL; Aitelli CL; Osborne CR; Izatt T; Kurdoglu A; Baker A; Koeman J; Barbacioru C; Sakarya O; De La Vega FM; Siddiqui A; Hoang L; Billings PR; Salhia B; Tolcher AW; Trent JM; Mousses S; Von Hoff D; Carpten JD
Mol Cancer Ther; 2013 Jan; 12(1):104-16. PubMed ID: 23171949
[TBL] [Abstract][Full Text] [Related]
6. The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.
Wander SA; Cohen O; Gong X; Johnson GN; Buendia-Buendia JE; Lloyd MR; Kim D; Luo F; Mao P; Helvie K; Kowalski KJ; Nayar U; Waks AG; Parsons SH; Martinez R; Litchfield LM; Ye XS; Yu C; Jansen VM; Stille JR; Smith PS; Oakley GJ; Chu QS; Batist G; Hughes ME; Kremer JD; Garraway LA; Winer EP; Tolaney SM; Lin NU; Buchanan SG; Wagle N
Cancer Discov; 2020 Aug; 10(8):1174-1193. PubMed ID: 32404308
[TBL] [Abstract][Full Text] [Related]
7. Transcriptomic Profiling of Sequential Tumors from Breast Cancer Patients Provides a Global View of Metastatic Expression Changes Following Endocrine Therapy.
McBryan J; Fagan A; McCartan D; Bane FT; Varešlija D; Cocchiglia S; Byrne C; Bolger J; McIlroy M; Hudson L; Tibbitts P; Gaora PÓ; Hill AD; Young LS
Clin Cancer Res; 2015 Dec; 21(23):5371-9. PubMed ID: 26240272
[TBL] [Abstract][Full Text] [Related]
8. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.
Mak MP; Tong P; Diao L; Cardnell RJ; Gibbons DL; William WN; Skoulidis F; Parra ER; Rodriguez-Canales J; Wistuba II; Heymach JV; Weinstein JN; Coombes KR; Wang J; Byers LA
Clin Cancer Res; 2016 Feb; 22(3):609-20. PubMed ID: 26420858
[TBL] [Abstract][Full Text] [Related]
9. Single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer tumors.
Wang R; Li J; Zhou X; Mao Y; Wang W; Gao S; Wang W; Gao Y; Chen K; Yu S; Wu X; Wen L; Ge H; Fu W; Tang F
Genome Med; 2022 Aug; 14(1):93. PubMed ID: 35974387
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Genomic Profiling Aids in Distinguishing Metastatic Recurrence from Second Primary Cancers.
Weinberg BA; Gowen K; Lee TK; Ou SI; Bristow R; Krill L; Almira-Suarez MI; Ali SM; Miller VA; Liu SV; Klempner SJ
Oncologist; 2017 Feb; 22(2):152-157. PubMed ID: 28193735
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Predictive Biomarkers of the Response to Pazopanib Based on an Integrative Analysis of High-grade Soft-tissue Sarcomas: Analysis of a Tumor Sample from a Responder and Patients with Other Soft-tissue Sarcomas.
Suehara Y; Kohsaka S; Yamaguchi S; Hayashi T; Kurihara T; Sano K; Sasa K; Akaike K; Ueno T; Kojima S; Ikegami M; Mizuno S; Okubo T; Kim Y; Kaneko K; Saito T; Kato S; Mano H
Clin Orthop Relat Res; 2020 Nov; 478(11):2461-2476. PubMed ID: 32567826
[TBL] [Abstract][Full Text] [Related]
12. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.
Hatzis C; Pusztai L; Valero V; Booser DJ; Esserman L; Lluch A; Vidaurre T; Holmes F; Souchon E; Wang H; Martin M; Cotrina J; Gomez H; Hubbard R; Chacón JI; Ferrer-Lozano J; Dyer R; Buxton M; Gong Y; Wu Y; Ibrahim N; Andreopoulou E; Ueno NT; Hunt K; Yang W; Nazario A; DeMichele A; O'Shaughnessy J; Hortobagyi GN; Symmans WF
JAMA; 2011 May; 305(18):1873-81. PubMed ID: 21558518
[TBL] [Abstract][Full Text] [Related]
13. Predicting censored survival data based on the interactions between meta-dimensional omics data in breast cancer.
Kim D; Li R; Dudek SM; Ritchie MD
J Biomed Inform; 2015 Aug; 56():220-8. PubMed ID: 26048077
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers.
Horak P; Heining C; Kreutzfeldt S; Hutter B; Mock A; Hüllein J; Fröhlich M; Uhrig S; Jahn A; Rump A; Gieldon L; Möhrmann L; Hanf D; Teleanu V; Heilig CE; Lipka DB; Allgäuer M; Ruhnke L; Laßmann A; Endris V; Neumann O; Penzel R; Beck K; Richter D; Winter U; Wolf S; Pfütze K; Geörg C; Meißburger B; Buchhalter I; Augustin M; Aulitzky WE; Hohenberger P; Kroiss M; Schirmacher P; Schlenk RF; Keilholz U; Klauschen F; Folprecht G; Bauer S; Siveke JT; Brandts CH; Kindler T; Boerries M; Illert AL; von Bubnoff N; Jost PJ; Spiekermann K; Bitzer M; Schulze-Osthoff K; von Kalle C; Klink B; Brors B; Stenzinger A; Schröck E; Hübschmann D; Weichert W; Glimm H; Fröhling S
Cancer Discov; 2021 Nov; 11(11):2780-2795. PubMed ID: 34112699
[TBL] [Abstract][Full Text] [Related]
15. Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer.
Chen WS; Aggarwal R; Zhang L; Zhao SG; Thomas GV; Beer TM; Quigley DA; Foye A; Playdle D; Huang J; Lloyd P; Lu E; Sun D; Guan X; Rettig M; Gleave M; Evans CP; Youngren J; True L; Lara P; Kothari V; Xia Z; Chi KN; Reiter RE; Maher CA; Feng FY; Small EJ; Alumkal JJ;
Eur Urol; 2019 Nov; 76(5):562-571. PubMed ID: 30928160
[TBL] [Abstract][Full Text] [Related]
16. Molecular characterization of the Ggamma-globin-Tag transgenic mouse model of hormone refractory prostate cancer: comparison to human prostate cancer.
Calvo A; Perez-Stable C; Segura V; Catena R; Guruceaga E; Nguewa P; Blanco D; Parada L; Reiner T; Green JE
Prostate; 2010 May; 70(6):630-45. PubMed ID: 20058236
[TBL] [Abstract][Full Text] [Related]
17. Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets.
Varešlija D; Priedigkeit N; Fagan A; Purcell S; Cosgrove N; O'Halloran PJ; Ward E; Cocchiglia S; Hartmaier R; Castro CA; Zhu L; Tseng GC; Lucas PC; Puhalla SL; Brufsky AM; Hamilton RL; Mathew A; Leone JP; Basudan A; Hudson L; Dwyer R; Das S; O'Connor DP; Buckley PG; Farrell M; Hill ADK; Oesterreich S; Lee AV; Young LS
J Natl Cancer Inst; 2019 Apr; 111(4):388-398. PubMed ID: 29961873
[TBL] [Abstract][Full Text] [Related]
18. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
19. Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patients.
Welt A; Tewes M; Aktas B; O Hoffmann O; Wiesweg M; Ting S; Reis H; Worm K; Richly H; Hense J; Palmer MR; Lee BH; Wendling J; Kossow J; Scheulen ME; Lehnerdt C; Kohl M; Derks C; Skottky S; Haus U; Schmid KW; Kimmig R; Schuler M; Kasper S
Breast Cancer Res Treat; 2013 Nov; 142(1):81-8. PubMed ID: 24122392
[TBL] [Abstract][Full Text] [Related]
20. Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort.
Leibowitz BD; Dougherty BV; Bell JSK; Kapilivsky J; Michuda J; Sedgewick AJ; Munson WA; Chandra TA; Dry JR; Beaubier N; Igartua C; Taxter T
BMC Cancer; 2022 May; 22(1):587. PubMed ID: 35643464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
